These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38602623)

  • 1. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review.
    Drysdale M; Berktas M; Gibbons DC; Rolland C; Lavoie L; Lloyd EJ
    Infection; 2024 Oct; 52(5):1839-1861. PubMed ID: 38602623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.
    Drysdale M; Gibbons DC; Singh M; Rolland C; Lavoie L; Skingsley A; Lloyd EJ
    Infection; 2024 Feb; 52(1):1-17. PubMed ID: 37776474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study.
    Drysdale M; Tibble H; Patel V; Gibbons DC; Lloyd EJ; Kerr W; Macdonald C; Birch HJ; Sheikh A
    BMC Infect Dis; 2024 Jul; 24(1):670. PubMed ID: 38965495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.
    Patel V; Levick B; Boult S; Gibbons DC; Drysdale M; Lloyd EJ; Singh M; Birch HJ
    BMC Infect Dis; 2024 Apr; 24(1):428. PubMed ID: 38649824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study.
    Patel V; Yarwood MJ; Levick B; Gibbons DC; Drysdale M; Kerr W; Watkins JD; Young S; Pierce BF; Lloyd EJ; Birch HJ; Kamalati T; Brett SJ
    Curr Med Res Opin; 2024 Aug; 40(8):1323-1334. PubMed ID: 38975862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium.
    Drysdale M; Hautekiet T; Singh M; Hautekiet J; Ludikhuyze L; Patel V; Gibbons DC; De Roeck D; Colpaert K; Lloyd EJ; Van Braeckel E
    Acta Clin Belg; 2024 Jun; 79(3):174-183. PubMed ID: 39081095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data.
    Russo A; Grimaldi P; Pisaturo M; Onorato L; Coppola N
    Front Immunol; 2024; 15():1295029. PubMed ID: 38352882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.
    Lo CKL; Lo CKF; Komorowski AS; Leung V; Matic N; McKenna S; Perez-Patrigeon S; Sheth PM; Lowe CF; Chagla Z; Bai AD
    BMC Res Notes; 2024 Jan; 17(1):37. PubMed ID: 38267971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records.
    Bell CF; Gibbons DC; Drysdale M; Birch HJ; Lloyd EJ; Patel V; Carpenter C; Carlson K; Calay ES; Puranik A; Wagner TE; O'Horo JC; Razonable RR
    PLoS One; 2024; 19(7):e0304822. PubMed ID: 39012863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
    Viruses; 2023 May; 15(6):. PubMed ID: 37376600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
    Mazzotta V; Cozzi Lepri A; Colavita F; Rosati S; Lalle E; Cimaglia C; Paulicelli J; Mastrorosa I; Vita S; Fabeni L; Vergori A; Maffongelli G; Carletti F; Lanini S; Caraffa E; Milozzi E; Libertone R; Piselli P; Girardi E; Garbuglia A; Vaia F; Maggi F; Nicastri E; Antinori A;
    J Med Virol; 2023 Jan; 95(1):e28186. PubMed ID: 36184918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.
    Zheng B; Tazare J; Nab L; Green AC; Curtis HJ; Mahalingasivam V; Herrett EL; Costello RE; Eggo RM; Speed V; Bacon SC; Bates C; Parry J; Cockburn J; Hester F; Harper S; Schaffer AL; Hulme WJ; Mehrkar A; Evans SJ; MacKenna B; Goldacre B; Douglas IJ; Tomlinson LA;
    Lancet Reg Health Eur; 2023 Nov; 34():100741. PubMed ID: 37927438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 18. Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
    Mazzotta V; Mazzaferri F; Lanini S; Mirandola M; Cozzi Lepri A; Vergori A; Savoldi A; Santoro A; Maccarrone G; Mastrorosa I; Simonetti O; Zottis F; Nicastri E; Rosini G; Rovigo L; Tavernaro L; Sarmati L; Tascini C; Girardi E; Cattelan AM; Antinori A; Tacconelli E;
    J Infect; 2024 Nov; 89(5):106294. PubMed ID: 39343244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.
    Behzad A; Mohamed A; Ali A; Niinuma S; Butler AE; Alqahtani M
    J Infect Public Health; 2024 Feb; 17(2):315-320. PubMed ID: 38160562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.
    Kikuchi K; Nangaku M; Ryuzaki M; Yamakawa T; Ota Y; Hanafusa N; Sakai K; Kanno Y; Ando R; Shinoda T; Wakino S; Nakamoto H; Takemoto Y; Akizawa T;
    Ther Apher Dial; 2023 Dec; 27(6):1064-1069. PubMed ID: 37395555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.